An increase in soluble forms of MICA/B (sMICA/B) has been detected in serum from melanoma patients, which correlates with poor survival in response to ipilimumab (anti-CTLA-4 mAb) treatment [35]. This evidence concerns the gene CTLA4 and melanoma.